BACKGROUND: The incidence of invasive group A Streptococcus (GAS) disease can vary over time and geographic region, possibly reflecting the population's susceptibility to particular strains but also variation in the predominant M/emm types. Canadian surveillance documented an epidemic of an uncommon M/emm59 type from 2006 to 2009. METHODS: Invasive GAS isolates are submitted by Public Health Laboratories in Canada to the National Centre for Streptococcus for M/emm typing. Patient age, sex, geographic location, and the anatomical source of isolate are provided with the isolate. When it was recognized that M/emm59 strains were increasing in prevalence, clinical information was collected on M/emm59 cases captured in Alberta and compared with cases of other M/emm types occurring in this province. RESULTS: From January 2006 through December 2009, 539 (13.0%) of 4150 invasive GAS cases were identified as M/emm59: 164 from British Columbia, 146 from Alberta, 62 from Saskatchewan, 82 from Manitoba, 68 from Ontario, 14 from Quebec, 1 from New Brunswick, 1 from Newfoundland, 1 from Yukon, and 1 from Nunavut. The predominant clinical presentation was bacteremia (45.0%) followed by cellulitis (41.4%). Compared with concurrent cases of invasive GAS disease caused by all other M/emm types, identified risk factors for M/emm59 disease were alcohol abuse (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.4-3.8), homelessness (OR, 2.0; 95% CI, 1.2-3.4), hepatitis C virus infection (OR, 2.0; 95% CI, 1.1-3.5), and illicit drug use (OR, 1.7; 95% CI, 1.0-3.0). CONCLUSIONS: Western Canada has witnessed the rapid emergence of a rare GAS strain causing invasive disease predominately in a select population of disadvantaged persons.
BACKGROUND: The incidence of invasive group A Streptococcus (GAS) disease can vary over time and geographic region, possibly reflecting the population's susceptibility to particular strains but also variation in the predominant M/emm types. Canadian surveillance documented an epidemic of an uncommon M/emm59 type from 2006 to 2009. METHODS: Invasive GAS isolates are submitted by Public Health Laboratories in Canada to the National Centre for Streptococcus for M/emm typing. Patient age, sex, geographic location, and the anatomical source of isolate are provided with the isolate. When it was recognized that M/emm59 strains were increasing in prevalence, clinical information was collected on M/emm59 cases captured in Alberta and compared with cases of other M/emm types occurring in this province. RESULTS: From January 2006 through December 2009, 539 (13.0%) of 4150 invasive GAS cases were identified as M/emm59: 164 from British Columbia, 146 from Alberta, 62 from Saskatchewan, 82 from Manitoba, 68 from Ontario, 14 from Quebec, 1 from New Brunswick, 1 from Newfoundland, 1 from Yukon, and 1 from Nunavut. The predominant clinical presentation was bacteremia (45.0%) followed by cellulitis (41.4%). Compared with concurrent cases of invasive GAS disease caused by all other M/emm types, identified risk factors for M/emm59 disease were alcohol abuse (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.4-3.8), homelessness (OR, 2.0; 95% CI, 1.2-3.4), hepatitis C virus infection (OR, 2.0; 95% CI, 1.1-3.5), and illicit drug use (OR, 1.7; 95% CI, 1.0-3.0). CONCLUSIONS: Western Canada has witnessed the rapid emergence of a rare GAS strain causing invasive disease predominately in a select population of disadvantaged persons.
Authors: M Montes; C Ardanuy; E Tamayo; A Domènech; J Liñares; E Pérez-Trallero Journal: Eur J Clin Microbiol Infect Dis Date: 2011-04-15 Impact factor: 3.267
Authors: Debra E Bessen; W Michael McShan; Scott V Nguyen; Amol Shetty; Sonia Agrawal; Hervé Tettelin Journal: Infect Genet Evol Date: 2014-10-30 Impact factor: 3.342
Authors: Herman Tse; Jessie Y J Bao; Mark R Davies; Peter Maamary; Hoi-Wah Tsoi; Amy H Y Tong; Tom C C Ho; Chi-Ho Lin; Christine M Gillen; Timothy C Barnett; Jonathan H K Chen; Mianne Lee; Wing-Cheong Yam; Chi-Kin Wong; Cheryl-Lynn Y Ong; Yee-Wai Chan; Cheng-Wei Wu; Tony Ng; Wilina W L Lim; Thomas H F Tsang; Cindy W S Tse; Gordon Dougan; Mark J Walker; Si Lok; Kwok-Yung Yuen Journal: J Infect Dis Date: 2012-05-21 Impact factor: 5.226
Authors: Misu Sanson; Brian E O'Neill; Priyanka Kachroo; Jeff R Anderson; Anthony R Flores; Chandni Valson; Concepcion C Cantu; Nishanth Makthal; Christof Karmonik; Nahuel Fittipaldi; Muthiah Kumaraswami; James M Musser; Randall J Olsen Journal: Am J Pathol Date: 2014-12-02 Impact factor: 4.307
Authors: Sandra J Valenciano; Jennifer Onukwube; Michael W Spiller; Ann Thomas; Kathryn Como-Sabetti; William Schaffner; Monica Farley; Susan Petit; James P Watt; Nancy Spina; Lee H Harrison; Nisha B Alden; Salina Torres; Melissa L Arvay; Bernard Beall; Chris A Van Beneden Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Taryn B T Athey; Sarah Teatero; Lee E Sieswerda; Jonathan B Gubbay; Alex Marchand-Austin; Aimin Li; Jessica Wasserscheid; Ken Dewar; Allison McGeer; David Williams; Nahuel Fittipaldi Journal: J Clin Microbiol Date: 2015-10-21 Impact factor: 5.948
Authors: Emily Mosites; Anna Frick; Prabhu Gounder; Louisa Castrodale; Yuan Li; Karen Rudolph; Debby Hurlburt; Kristen D Lecy; Tammy Zulz; Tolu Adebanjo; Jennifer Onukwube; Bernard Beall; Chris A Van Beneden; Thomas Hennessy; Joseph McLaughlin; Michael G Bruce Journal: Clin Infect Dis Date: 2018-03-19 Impact factor: 9.079
Authors: Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet Journal: Clin Microbiol Rev Date: 2014-04 Impact factor: 26.132
Authors: Sarah Teatero; Allison McGeer; Gregory J Tyrrell; Linda Hoang; Hanan Smadi; Marc-Christian Domingo; Paul N Levett; Michael Finkelstein; Ken Dewar; Agron Plevneshi; Taryn B T Athey; Jonathan B Gubbay; Michael R Mulvey; Irene Martin; Walter Demczuk; Nahuel Fittipaldi Journal: Open Forum Infect Dis Date: 2018-04-20 Impact factor: 3.835